Atopic dermatitis (AD) is a skin problem causing rash and itching due to skin inflammation. Some kids need medicine that affects the whole body, not just creams. This study compares two medicines: upadacitinib (a pill) and dupilumab (an injection) for kids aged 2 to under 12 with moderate to severe AD. Upadacitinib is usually for older kids (12+), but this study tests it in younger kids. The study lasts up to 160 weeks, with regular check-ups at hospitals or clinics.
About 675 kids worldwide will participate, and only 1 in 5 will get dupilumab. Participants will receive upadacitinib daily or dupilumab every 2 to 4 weeks. Doctors will check the treatment effects with blood tests, side effect monitoring, and questionnaires.
- The study may have more visits than usual care.
- Parents should be aware of the 160-week duration.
- Participation involves regular hospital or clinic visits.
How understandable was the trial content above?
Hard to understand
Easy to understand